Pepgen Inc. (PEPG)
$9
Market is closed - opens 7 PM, 04 Oct 2024
Performance
- $8.73$9.28$9.00
3.0%
Downside
Day's Volatility :5.93%
Upside
3.02%
- $3.72$19.30$9.00
58.67%
Downside
52 Weeks Volatility :80.72%
Upside
53.36%
Returns
| Period | Pepgen Inc. | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -48.74% | 7.5% | 0.0% |
6 Months | -21.34% | 6.9% | 0.0% |
1 Year | 84.67% | 20.9% | 0.0% |
3 Years | -28.15% | 21.0% | -21.1% |
Highlights
Market Capitalization | 287.4M |
Book Value | $4.76 |
Earnings Per Share (EPS) | -3.31 |
Wall Street Target Price | 19.6 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -31.89% |
Return On Equity TTM | -58.97% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -94.4M |
Diluted Eps TTM | -3.31 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.16 |
EPS Estimate Next Year | -2.82 |
EPS Estimate Current Quarter | -0.72 |
EPS Estimate Next Quarter | -0.73 |
Analyst Recommendation
Buy
90%Buy
9%Hold
0
0%Sell
Based on 11 Wall street analysts offering stock ratings for Pepgen Inc.(by analysts ranked 0 to 5 stars)
Based on 11 analyst
- Current
- 1M Ago
- 3M Ago
Buy
10
10
10
Hold
1
1
1
Sell
00
00
00
Analyst Forecast
What analysts predicted
Upside of 117.78%
Current $9.00
Target $19.60
Technicals Summary
Sell
Neutral
Buy
Pepgen Inc. is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Pepgen Inc. | -6.46% | -21.34% | 84.67% | -28.15% | -28.15% |
 Regeneron Pharmaceuticals, Inc. | -10.06% | 10.55% | 30.05% | 89.27% | 274.48% |
 Novo Nordisk A/s | -12.62% | -6.24% | 35.65% | 145.66% | 372.59% |
 Alnylam Pharmaceuticals, Inc. | 8.37% | 82.34% | 59.06% | 41.03% | 258.58% |
 Vertex Pharmaceuticals Incorporated | -2.23% | 13.76% | 34.75% | 162.16% | 172.77% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Pepgen Inc. | NA | NA | NA | -3.16 | -0.59 | -0.32 | NA | 4.76 |
Regeneron Pharmaceuticals, Inc. | 27.85 | 27.85 | 1.43 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.39 | 40.39 | 1.82 | 3.45 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.49 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.56 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Pepgen Inc. | Buy | $287.4M | -28.15% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $115.9B | 274.48% | 27.85 | 32.04% |
Novo Nordisk A/s | Buy | $531.4B | 372.59% | 40.39 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $35.3B | 258.58% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.0B | 172.77% | 32.84 | -4.74% |
Institutional Holdings
RA Capital Management, LLC
32.80%Suvretta Capital Management, LLC
4.67%Viking Global Investors LP
4.55%Perceptive Advisors LLC
4.33%Adage Capital Partners Gp LLC
4.07%BlackRock Inc
3.19%
Company Information
Organization | Pepgen Inc. |
Employees | 72 |
CEO | Dr. James G. McArthur Ph.D. |
Industry | Services |
